Navigation Links
Researchers identify unusual molecular switch for common form of advanced breast cancer
Date:11/8/2007

New evidence demonstrates that a novel molecular switch is involved in the development of a common form of advanced breast cancer, known as locally advanced breast cancer. The research, published by Cell Press in the November 9, 2007 issue of Molecular Cell, provides an exciting paradigm shift in the understanding of a key event in breast cancer development and presents new therapeutic opportunities for this deadly disease.

Locally advanced breast cancers are typically large tumors that, remarkably, have rarely spread to form additional tumors in distant sites in the body when they are discovered. However, locally advanced breast cancer patients often have a high level of treatment failure as the disease is often detected at an advanced stage. Previous work has shown that for large tumors to progress they must develop their own blood supply through a process known as tumor angiogenesis. Angiogenesis is often triggered as the expanding tumor cells move away from the existing blood supply and are deprived of oxygen, a condition known as hypoxia.

The ability of tumors to develop their own vasculature limits their growth and is regulated at different levels of genetic control. Now, a research study led by Drs. Robert J. Schneider and Silvia C. Formenti of New York University School of Medicine presents new evidence demonstrating how an unorthodox second pathway in protein synthesis plays a key role in controlling the translation of genetic messages (mRNAs) for factors that orchestrate angiogenesis, the tumor response to hypoxia and progression of tumors to form large locally advanced breast cancers. Our study shows that an unusual molecular switch occurs in the machinery that carries out synthesis of proteins that are essential for angiogenesis and tumor progression, explains Dr. Schneider.

Drs. Schneider, Formenti and colleagues demonstrate that two factors involved in protein synthesis, 4E-BP1 and eIF4G, are strongly over-expressed in the majority of human large advanced breast tumors. Using breast cancer cells and animal tumor models, the researchers observed that elevated levels of 4E-BP1 trigger hypoxia inhibition of conventional protein synthesis in tumor cells, and with eIF4G, then increases the selective translation of specific mRNAs that promote tumor survival and angiogenesis, thereby functioning as a hypoxia controlled switch for tumor growth and survival.

These results present a entirely new understanding of the control of breast cancer angiogenesis that places the regulation of protein synthesis as a key event in malignant breast cancer. This research opens new avenues for the development of targeted approaches in the treatment of one of the most common lethal forms of breast cancer worldwide, says Dr. Formenti. The work was funded by the Breast Cancer Research Foundation and the Department of Defense Breast Cancer Research Program.


'/>"/>

Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. UCLA researchers identify markers that may predict diabetes in still-healthy people
3. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
4. Bipolar disorder relapses halved by Melbourne researchers
5. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
6. High and mighty: first common height gene identified by researchers behind obesity gene finding
7. Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD
8. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
9. Researchers develop long-lasting growth hormone
10. Jefferson immunology researchers halt lethal rabies infection in brain
11. Purdue researchers develop technology to detect cancer by scanning surface veins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 13, 2017 , ... The American Board of Family Medicine's (ABFM) Board of ... Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will serve ... Puffer’s retirement at the end of 2018. Upon assuming the role of President and ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, ... guideline updates for the primary prevention of cardiovascular diseases during the 15th ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term ... long-term care insurance companies have a waiver for care if the client has a ... when the family pays for care, is often waived, so the benefits from their ...
(Date:10/13/2017)... ... 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out ... free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting ... children of all ages; it is a non-competitive, non-timed event, which is all about ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Agile Software Development, has been awarded a contract by the Center for Medicare ... (BPA) aims to accelerate the enterprise use of Agile methodologies in a consistent ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... 2017 AVACEN Medical (AVACEN) announced that its ... helping those with the widespread pain associated with fibromyalgia ... in Essex, England commented, "I ... experiencing no sleep at all, tremendous pain, with every ... recommend [the AVACEN 100] enough, how this has and ...
(Date:9/18/2017)... , Sept. 18, 2017 ... fields of bioinformatics and immune engineering, today ... protective avian influenza A (H7N9) vaccine. ... related to seasonal influenza and presents a ... on prior exposure to be effective. Using ...
(Date:9/12/2017)... Sept. 12, 2017  ValGenesis Inc., the global ... is pleased to announce the appointment of Dr. ... its Board of Directors and Chairman of Advisory ... life science companies to manage their entire validation ... paper in this process. Furthermore, ValGenesis VLMS enables ...
Breaking Medicine Technology: